文献速递核素与放射性配体治疗肿瘤 PET/CT

重复131I-MIBG放疗对转移性神经内分泌肿瘤大小及代谢活性的影响

Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2020-10-16

本研究前瞻性纳入11例转移性神经内分泌肿瘤患者,每6个月重复给予5,550 MBq的131I-MIBG治疗,共31次,平均2.8次,累积剂量15,640.9 MBq。CT评估3例部分缓解、6例稳定、2例进展;在部分缓解和稳定患者中肿瘤直径显著缩小,且高血压患者舒张压显著降低。

要点

  • 重复131I-MIBG治疗每6个月5,550 MBq,累积剂量15,640.9 MBq。
  • RECIST评估:3例部分缓解,6例稳定,2例进展。
  • 部分缓解和稳定患者中肿瘤直径从16 mm降至11 mm(P<0.001)。

研究设计与样本

  • 前瞻性研究,纳入11例转移性神经内分泌肿瘤患者(年龄49.2±16.3岁),每6个月重复给予5,550 MBq的131I-MIBG治疗,共31次,平均2.8±0.4次,累积剂量15,640.9±2,245.1 MBq(286.01 MBq/kg)。

主要发现

  • 基于CT的RECIST评估:3例部分缓解,6例稳定,2例进展。
  • 全部患者 summed length diameter 中位数从228.7 mm(IQR 37.0-336.0 mm)变为171.0 mm(IQR 38.0-270.0 mm),P=0.563。
  • 在部分缓解和稳定患者(n=9)的肿瘤区域分析中,131I-MIBG治疗显著缩小肿瘤直径(79个病灶;中位数16 mm [IQR 12-22 mm] 降至11 mm [IQR 6-16 mm];P<0.001)。
  • 5例高血压患者中,收缩压降低呈强趋势(P=0.058),舒张压显著降低(P=0.006)。

关键数值与推荐

  • 重复治疗方案:每6个月给予5,550 MBq的131I-MIBG,平均2.8次,累积剂量15,640.9 MBq。
  • 肿瘤反应评估采用CT(RECIST)和18F-FDG PET或18F-FDG PET/CT,在最终治疗后3-6个月进行。

临床怎么用

  • 对于转移性神经内分泌肿瘤患者,重复131I-MIBG治疗可作为治疗方案的一种选择,可能抑制疾病进展并缩小肿瘤。

局限性

  • 样本量小(11例),无对照组,需要更大规模的前瞻性对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

131I-meta-iodobenzylguanidine (131I-MIBG) radiotherapy has shown some survival benefits in metastatic neuroendocrine tumors (NETs). European Association of Nuclear Medicine clinical guidelines for 131I-MIBG radiotherapy suggest a repeated treatment protocol, although none currently exists. The existing single-high-dose 131I-MIBG radiotherapy (444 MBq/kg) has been shown to have some benefits for patients with metastatic NETs. However, this protocol increases adverse effects and requires alternative therapeutic approaches. Therefore, the aim of this study was to evaluate the effects of repeated 131I-MIBG therapy on tumor size and tumor metabolic response in patients with metastatic NETs. Methods: Eleven patients with metastatic NETs (aged 49.2 ± 16.3 y) prospectively received repeated 5,550-MBq doses of 131I-MIBG therapy at 6-mo intervals. In total, 31 treatments were performed. The mean number of treatments was 2.8 ± 0.4, and the cumulative 131I-MIBG dose was 15,640.9 ± 2,245.1 MBq (286.01 MBq/kg). Tumor response was observed by CT and 18F-FDG PET or by 18F-FDG PET/CT before and 3-6 mo after the final 131I-MIBG treatment. Results: On the basis of the CT findings with RECIST, 3 patients showed a partial response and 6 patients showed stable disease. The remaining 2 patients showed progressive disease. Although there were 2 progressive-disease patients, analysis of all patients showed no increase in summed length diameter (median, 228.7 mm [interquartile range (IQR), 37.0-336.0 mm] to 171.0 mm [IQR, 38.0-270.0 mm]; P = 0.563). In tumor region-based analysis with partial-response and stable-disease patients (n = 9), 131I-MIBG therapy significantly reduced tumor diameter (79 lesions; median, 16 mm [IQR, 12-22 mm] to 11 mm [IQR, 6-16 mm]; P < 0.001). Among 5 patients with hypertension, there was a strong trend toward systolic blood pressure reduction (P = 0.058), and diastolic blood pressure was significantly reduced (P = 0.006). Conclusion: Eighty-two percent of metastatic NET patients effectively achieved inhibition of disease progression, with reduced tumor size and reduced metabolic activity, through repeated 131I-MIBG therapy. Therefore, this relatively short-term repeated 131I-MIBG treatment may have potential as one option in the therapeutic protocol for metastatic NETs. Larger prospective studies with control groups are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yoshinaga K, Abe T, Okamoto S, et al. Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors. J Nucl Med. 2020. PMID: 33067337. doi:10.2967/jnumed.120.250803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。